ArticleClinical and experimental medicine2019
Comparison between clinical significance of serum CXCL-8 and classical tumor markers in oesophageal cancer (OC) patients.
Article in Clinical and experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 31 citations in OpenAlex.
- Study on the Diagnosis of Gastric Cancer by Magnetic Beads Extraction and Mass Spectrometry.BioMed research international · 2020Trial
- Comparison of the clinical usefulness of CXCL-8 and conventional clinical tumor markers for gastric cancer diagnosis.Clinics (Sao Paulo, Brazil) · 2026Article
- Nutrients Lowering Obesity-Linked Chemokines Blamable for Metastasis.International journal of molecular sciences · 2025Review
- Low Serum Cholinesterase Levels Predict Poor Prognosis in Patients with Ovarian Cancer.International journal of general medicine · 2025Article
- Article
- Designing a CXCL8-hsa chimera as potential immunmodulator of the tumor micro-environment.Frontiers in immunology · 2025Article
- Chemokines and Their Receptors: Predictors of Therapeutic Potential in Tumor Microenvironment on Esophageal Cancer.Digestive diseases and sciences · 2024Review
- Exploring Potential Biomarkers in Oesophageal Cancer: A Comprehensive Analysis.International journal of molecular sciences · 2024Review
- Development and Validation of a Pathomics Model Using Machine Learning to Predict CXCL8 Expression and Prognosis in Head and Neck Cancer.Clinical and experimental otorhinolaryngology · 2024Article
- Expression of CXCL8 and its relationship with prognosis in patients with non-small cell lung cancer.American journal of cancer research · 2024Article
- CXCL5 and CXCL14, but not CXCL16 as potential biomarkers of colorectal cancer.Scientific reports · 2023Article
- The Significance of CXCL1 and CXCR1 as Potential Biomarkers of Colorectal Cancer.Biomedicines · 2023Article
- Interleukin-8 and Interleukin-6 Are Biomarkers of Poor Prognosis in Esophageal Squamous Cell Carcinoma.Cancers · 2023Article
- Mechanisms of esophageal cancer metastasis and treatment progress.Frontiers in immunology · 2023Review
- Prognostic Significance of the CXCLs and Its Impact on the Immune Microenvironment in Ovarian Cancer.Disease markers · 2023Article
- The Significance of Selected C-C Motif Chemokine Ligands in Colorectal Cancer Patients.Journal of clinical medicine · 2022Article
- Comprehensive analysis of the expression and significance of CXCLs in human diffuse large B-cell lymphoma.Scientific reports · 2022Article
- Comparison between Clinical Utility of CXCL-8 and Clinical Practice Tumor Markers for Colorectal Cancer Diagnosis.BioMed research international · 2022Article
- Therapeutic Influence on Important Targets Associated with Chronic Inflammation and Oxidative Stress in Cancer Treatment.Cancers · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
C-X-C motif chemokine 8 (CXCL-8), known as interleukin-8, is a pro-inflammatory cytokine which acts as a chemotactic factor, mainly for leukocytes. CXCL-8 is produced by malignant cells, and therefore it can stimulate the growth and progression of various neoplasms, including oesophageal cancer (OC). The aim of the current study was to measure serum concentrations of chemokine CXCL-8 in OC patients and establish whether this protein might be considered a potential candidate for a tumor marker in the diagnosis and progression of OC. The study included 50 OC subjects (32 patients with squamous cell carcinoma of oesophagus-OSCC, 18 patients with adenocarcinoma-OAC) and 26 healthy volunteers. Serum CXCL-8 concentrations were measured using immunoenzymatic assay (ELISA). CRP levels were determined by immunoturbidimetric method, while classical tumor marker levels were measured using chemiluminescent immunoassay. CXCL-8 concentrations were significantly higher in OC patients compared to healthy controls. We demonstrated significant differences between CXCL-8 concentrations and depth of tumor invasion (T factor) in OC patients and OSCC subgroup. In addition, CXCL-8 levels were found to correlate positively with T factor and CRP concentrations. The diagnostic sensitivity, negative predictive value and the area under ROC curve (AUC) of CXCL-8 were higher than those of classical tumor markers. Our findings suggest the potential usefulness of CXCL-8 in the diagnosis and progression of OC. However, due to the non-specific nature of this chemokine, further research is needed to clarify the usefulness of CXCL-8 as a tumor marker of OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.